Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin vs Linezolid in CABP
NCT02269644Phase 3Withdrawn
- Sponsor
- Allergan
- Start
- Nov 2015
- Primary completion
- Nov 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dalbavancin in community-acquired bacterial pneumonia (CAP), sponsored by Allergan. Planned start Nov 2015; status: withdrawn.
02
Drugs
dalbavancin
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT02269644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02269644.